Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine
NEW BRUNSWICK, N.J., December 15, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion for use of the Company’s COVID-19 vaccine as a booster for adults aged 18 and older at least two months after primary vaccination with a single-shot of the Johnson & Johnson COVID-19 vaccine, and as a ‘mix and match’ booster following primary vaccination with an approved two-shot mRNA COVID-19 vaccine regimen (known as heterologous boosting). “We are pleased with today’s Positive Opinion from the CHMP supporting the use of our COVID-19 vaccine as a booster for eligible individuals in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson. “There is a growing body of data showing that the Johnson & Johnson COVID-19 vaccine induces broad and durable humoral and cellular immune responses, whether administered as a single shot for an efficient response to the pandemic, or as a booster shot after at least two months to strengthen protection against symptomatic COVID-19. Cellular immune responses are showing potential to be important for both breadth of protection and durability.”The CHMP Opinion was based on a comprehensive data package that included results from the Phase 3 ENSEMBLE 2 study, which found a booster of the Johnson & Johnson COVID-19 vaccine given two ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Allergy | Allergy & Immunology | Biotechnology | Bleeding | Brain | Cancer & Oncology | Cardiology | Cardiovascular | Centers for Disease Control and Prevention (CDC) | Clinical Trials | Coronavirus | COVID-19 | Emergency Medicine | Environmental Health | European Medicines Agency (EMA) | Eyes | Guillain-Barr Syndrome | Headache | Health Management | Heart | Hospitals | Hypertension | Infectious Diseases | International Medicine & Public Health | Israel Health | Learning | Legislation | Marketing | Men | Middle East Health | Migraine | Neurology | Neuroscience | Pain | Pandemics | Pfizer | Pharmaceuticals | Pregnancy | Pulmonary Hypertension | Respiratory Medicine | SARS | Science | Skin | Study | Tinnitus | Universities & Medical Training | USA Health | Vaccines | WHO